Background-Few studies simultaneously investigated lipids and lipoprotein biomarkers as predictors of ischemic stroke.
D
yslipidemia plays an essential role in the initiation and progression of atherosclerosis and its clinical consequences. [1] [2] [3] An abundance of data supports the relationship between abnormal lipid and lipoprotein biomarkers and the development of atherosclerosis and ischemic heart disease. 4 -8 Standard lipid testing, supported by the National Cholesterol Education Program, the United States Preventative Services Task Force, and the American Heart Association/American College of Cardiology, includes total cholesterol, highdensity lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). 9 -11 Several lipid and lipoprotein biomarkers have been proposed as potential risk factors for improved detection of subclinical disease. [12] [13] [14] In particular, clinical interest has focused on emerging lipoprotein parameters such as LDL and HDL particle number and size, intermediate-density lipoprotein (IDL) particle number, and lipoprotein (a). Direct comparisons of the magnitude of predictive value associated with each of these parameters have been rare. Furthermore, it is controversial whether any of these biomarkers has independent prognostic value.
Studies evaluating the relationship between lipid biomarkers and the risk of stroke have reported varied associations. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Much of the discrepancy may be based on differences in methodology, population studied, and differences of end points analyzed. In a large evaluation of 45 observational studies, 15 total cholesterol was associated with stroke only in participants under 45 years of age. More recent reports have noted a small but significant association between established lipid biomarkers and risk of ischemic stroke. 17, 20 Importantly, most studies used a combined end point of all stroke, either predominantly or exclusively enrolled men, and only evaluated established lipid biomarkers, including total cholesterol, HDL-C, and LDL-C. A report from the Women's Health Study 20 demonstrated a significant association of total and LDL-C with future ischemic stroke, but triglycerides and lipoprotein biomarkers were not evaluated. Recent data suggest that triglycerides are independently associated with the risk of stroke. 21 Because no prior study examined relations of all of these lipid and lipoprotein biomarkers with the risk of stroke in a single cohort, the relative usefulness of each biomarker is unknown.
We prospectively examined the association between lipid and lipoprotein biomarkers and the risk of ischemic stroke among postmenopausal women in a nested case-control analysis.
Methods

Study Participants
Study subjects were all participants in the Hormones and Biomarkers Predicting Stroke (HaBPS) Study, a prospective, case-control study of 972 ischemic stroke subjects and 972 matched control subjects nested within the Women's Health Initiative Observational Study (WHI-OS). The design and methods of the WHI-OS have been described in detail previously. 25, 26 Briefly, the WHI-OS, conducted in 40 clinical centers across the United States, was designed to examine the impact of a number of factors on many of the major causes of morbidity and mortality in postmenopausal women. Women eligible for the study were 50 -79 years of age at baseline, were postmenopausal, had no medical conditions associated with a predicted survival of Ͻ3 years, and provided informed consent to be a part of the study, as approved by the institutional review boards. Women were enrolled into the WHI-OS from 1993-1998. The stroke cases and control subjects in the present study come from the 93 676 women enrolled in WHI-OS, with mean follow-up in control subjects of 7.9 years (SDϭ1.3 years; range, 1.9 -10.5 years.
Of the 93 676 participants in the WHI-OS, 10 458 were excluded from consideration for the HaBPS study: 9831 did not meet the eligibility criteria of HaBPS, which were no history of myocardial infarction or stroke and adequate blood sample available for the biomarker assays. In addition, 627 participants with a locally adjudicated ischemic stroke were not adjudicated by central adjudication at the time of this study and were therefore excluded as cases or control subjects. The first confirmed 972 ischemic stroke cases were identified from among the 82 591 remaining participants. Control selection was done in a time-forward manner, selecting 1 control subject for each case from the risk set at the time of the case's event. Matching was performed on age at screening (Ϯ2 years), race/ethnicity, date of study enrollment (Ϯ3 months), and follow-up time (control follow-up time more than or equal to case follow-up time). Race/ethnicity was matched exactly, and the continuous matching variables were selected based on a criterion to minimize an overall distance measure. Cases and control subjects were pulled from separate datasets, so cases could not be selected as control subjects.
Data Collection
All women enrolled in WHI-OS completed baseline visits to determine eligibility and collect data including questionnaires, physical examinations, biological specimens, and laboratory tests. During the first screening visit, a physical examination was performed by certified staff using standardized procedures. Questionnaires queried the women on lifestyle factors, medical history, and personal habits. Women were asked to bring all their prescription medications in their original bottles to the baseline visit. The names, strengths, and form of the medications were transcribed from the label into a pharmacy database: the Master Drug Data Base (MDDB: Medi-Span, Indianapolis, IN) and were then assigned a therapeutic drug class from the American Hospital Formulary Service. Fasting blood samples were collected by following a standardized protocol. Samples were labeled, centrifuged, and frozen on site in Ϫ70°C freezers and later shipped to the central WHI specimen repository (McKesson BioServices, Rockville, MD) for long-term storage.
Laboratory Analyses
The case and control samples were extracted from the specimen archive and sent to LipoScience, Inc (Raleigh, NC) for lipoprotein particle analysis using an automated nuclear magnetic resonance (NMR) spectroscopic assay. 27 Particle concentrations of VLDL and LDL (including IDL) in nmol/L units and HDL in mol/L units were determined by summing the concentrations of their respective subclasses, which were obtained from the measured amplitudes of the distinct lipid methyl group NMR signals they emit. Concentrations of IDL particles (diameter range, 23-27 nm) were also provided, as were estimates of very low-density lipoprotein (VLDL) triglyceride (mg/dL) levels. 27 Weighted-average VLDL, LDL, and HDL particle sizes were calculated by summing the diameter of each subclass multiplied by its relative mass percentage as estimated by the amplitude of its methyl NMR signal. Interassay reproducibility, determined from replicate analyses of plasma pools, is indicated by the following coefficients of variation: Ͻ2% for VLDL size, Ͻ0.5% for LDL and HDL size, Ͻ5% for VLDL triglyceride and VLDL, LDL, and HDL particle concentrations, and Ͻ15% for IDL particle concentration. Total cholesterol, HDL-C, and triglycerides were measured by standard enzymatic assays at Medical Research Laboratories (Highland Heights, KY). LDL-C was calculated using the Friedewald formula. All lipid and lipoprotein analyses were conducted in randomly ordered case-control pairs to minimize systematic bias and interassay variation.
Follow-Up and Outcome Ascertainment
Study subjects were followed annually by mail or telephone to determine outcomes and overnight hospitalizations. Reports from participants or third party sources were also triggers for further investigation. Specific details of the illness and hospitalizations were obtained from medical records and laboratory results and other data were presented for adjudication locally by trained physician adjudicators who assigned a diagnosis according to standard criteria. All of the locally adjudicated strokes were sent for central adjudication by trained neurologists. Locally adjudicated cases not verified during central adjudication as being a stroke were excluded, thus only centrally adjudicated ischemic strokes were selected as outcomes. Ischemic stroke was defined as the rapid onset of a persistent neurological deficit attributed to an obstruction lasting more than 24 hours without evidence for other causes, unless death supervened or there was a demonstrable lesion compatible with acute stroke on computed tomography or MRI scan. Only stroke events that required hospitalization were considered as a potential outcome. Strokes were classified as ischemic or hemorrhagic on review of reports of brain imaging studies. Ischemic stroke subtype was based on the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) criteria. 28 Transient ischemic attacks or hemorrhagic strokes were not included in the definition of stroke outcome.
Statistical Analyses
Univariate analyses were conducted to evaluate differences in covariates between matched cases and control subjects, using McNemar 2 test for categorical variables, paired t tests for normally distributed continuous variables, and Wilcoxon matched-pairs, signed-rank test for nonnormally distributed variables. Spearman correlations between lipid and lipoprotein biomarkers were calculated among the control subjects to determine the relationships and to assess for multicollinearity. The relationship between lipid and lipoprotein biomarkers and risk of incident ischemic stroke was examined by using conditional logistic regression to account for the matching to estimate odds ratios (ORs) and 95% confidence intervals (CI) for quartiles of lipid biomarkers, with category cut-points defined according to the distribution of the control subjects with lipid values. Tests of linear trend across quartiles of lipid and lipoprotein biomarkers were conducted by assigning numeric values for each quartile and fitting this continuous variable in the model. Each lipid and lipoprotein biomarker was assessed independently in an adjusted model. Multivariable ORs were estimated from conditional logistic regression models, which accounted for the matching variables, and were additionally adjusted for several risk factors for ischemic stroke, including smoking status, body mass index, systolic blood pressure, use of antihypertensive medication, diabetes, and physical activity. Several analyses also adjusted for alcohol use, hormone therapy, and education status as a marker of socioeconomic status. Adjusted models were based on case-control pairs for whom complete data were available on all covariates of interest. Investigation of the effect of hormone therapy on the association of lipid and lipoprotein biomarkers and stroke was prespecified, and accordingly, unconditional logistic regression analyses were performed separately among hormone users and nonusers. All probability values were 2-tailed, and probability values Ͻ0.05 were considered statistically significant. STATA/SE 10.0 was used for all analyses (StataCorp LP, College Station, TX).
Results
Of the 972 matched pairs, there were 198 matched pairs that were excluded due to the case and/or control having used lipid-lowering therapy at baseline. Baseline characteristics of the 774 matched pairs that were used in this analysis are shown in Table 1 . Compared with control subjects, cases had higher body mass index and were more likely to be current smokers, hypertensive, and diabetic. No significant difference was noted in hormone use and alcohol use. As expected, among the control subjects, the lipid and lipoprotein parameters were highly intercorrelated ( Table 2) .
In bivariate analyses (Table 3) , cases had significantly higher median levels of triglycerides, IDL particles, LDL particles, LDL size, VLDL triglycerides, VLDL particles, and VLDL size. Additionally, median HDL-C levels and HDL size were significantly lower among control subjects compared with cases. Baseline levels of lipoprotein (a) were somewhat higher among the women with ischemic stroke than among control subjects, but these differences were not statistically significant. Similar results were demonstrated across quartiles and when comparing the fourth quartile of lipid biomarkers with the first quartile in unadjusted analyses (Table 4) . Of all traditional lipid biomarkers, the level of triglycerides was the only one associated with future ischemic stroke; the unadjusted OR for the highest versus lowest quartile was 1.96 (95% CI, 1.46 -2.10; P for trend Ͻ0.01).
When stratified by stroke subtype, lipid and lipoprotein biomarkers were most notably associated with ischemic stroke among subjects whose stroke etiology was from large artery atherosclerosis (online-only Data Supplement Table 1 ). Comparing the 4th quartile to the 1st quartile was significant for triglycerides (OR, 4.10; 95% CI, 1.82-9.27), HDL-C (OR, 0.29; 95% CI, 0.14 -0.63), LDL particle number (OR, 3.55; 95% CI, 1.63-7.73), VLDL triglycerides (OR, 5.38; 95% CI, 2.17-13.3), VLDL particle number (OR, 4.72; 95% CI, 2.02-11.05), and lipoprotein (a) (OR, 1.87; 95% CI, 0.96 -3.65.
In a multivariable model conditioned on age and race, and additionally adjusted for smoking status, body mass index, systolic blood pressure, use of antihypertensive medication, diabetes, and physical activity, the ORs of future ischemic stroke associated with each biomarker quartile are shown in Table 4 . Women in the highest quartile of triglycerides had a 56% increase in the odds of ischemic stroke versus those in the lowest quartile. Other lipid biomarkers associated with the odds of ischemic stroke after multivariable adjustment included VLDL size (P for trendϭ0.03) and IDL particle number (P for trendϭ0.02). Standard lipid biomarkers at baseline including total cholesterol, HDL-C, LDL-C, and the total cholesterol/HDL cholesterol ratio were not significantly Values are given as median (interquartile range) or percentage. *Diabetes was defined as being on treatment for diabetes or fasting glucose Ͼ126 mg/dL. associated with future ischemic stroke. Results of all models did not differ substantially with or without adjustment for body mass index. Additional adjustment for alcohol use, hormone therapy use, and education as a marker of socioeconomic status did not substantially change the multivariable associations presented in Table 4 (data not shown). Given the recognized relationship between diabetes and abnormal lipid and lipoprotein biomarkers, we repeated our analysis, excluding subjects with diabetes (nϭ184). In this nondiabetic sample, there remained an increase in the adjusted odds of ischemic stroke for triglycerides (OR, 1.59; P for trend Ͻ0.01), VLDL triglyceride (OR, 1.32; P for trendϭ0.06), VLDL size (OR, 1.51; P for trendϭ0.02), and LDL particle number (OR, 1.39; P for trendϭ0.04).
To explore whether triglyceride levels added independent information to standard-based screening, we computed the unadjusted OR of developing ischemic stroke in analyses that stratified patients into groups based on median lipid values. All unadjusted models conditioned on age and race. All adjusted models conditioned on age and race and additionally adjusted for smoking status, body mass index, systolic blood pressure, use of antihypertensive medication, diabetes, and physical activity.
Each row is a separate model with stroke as the outcome, which included quartiles of that specific biomarker. Biomarker quartile cut-points were based on all available control subjects. HDL indicates high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.
As shown in the Figure, the odds of developing ischemic stroke for triglyceride levels above the median (140 mg/dL) versus below the median was 32% (OR, 1.32; 95% CI, 0.99 -1.76) in women with LDL-C below the median and 52% (OR, 1.52; 95% CI, 1.14 -2.03) in those equal to or above the median. Similarly, elevated triglyceride levels were associated with increased odds of stroke in women with HDL-C below the median (OR, 1.38; 95% CI, 1.02-1.87) and equal to or above the median (OR, 1.34; 95% CI, 0.99 -1.79). To address the robustness of these findings, analyses were also performed using the total cholesterol/HDL-C ratio as the method of standard based screening (Figure) .
Hormone Therapy
Although the interaction of hormone use and lipids was not significantly associated with the odds of ischemic stroke, the association of lipid biomarkers was generally stronger in the nonusers of hormone therapy (online-only Data Supplement Table 2 ). In the multivariable adjusted model, the OR in the highest as compared with the lowest quartile of triglycerides was 1.77 in the nonusers (95% CI, 1.20 -2.62; P for trend Ͻ0.01) and 1.35 in the users of hormone therapy (95% CI, 0.81-2.26; P for trendϭ0.27). Similarly, in nonusers of hormone therapy, IDL particle number was associated with higher risk of ischemic stroke (OR, 1.93; 95% CI, 1.29 -2.88; P for trend Ͻ0.01) and HDL-C with lower risk (OR, 0.67; 95% CI, 0.44 -1.03; P for trendϭ0.09). Among users of hormone therapy, the corresponding OR was 0.94 for IDL particle number (95% CI, 0.58 -1.53; P for trendϭ0.96) and 1.04 for HDL-C (95% CI, 0.63-1.72; P for trendϭ0.97).
Clinical Cutoff Points for Established Lipid Biomarkers
We further categorized the study participants on the basis of proposed cutoff points for established lipid biomarkers, which are defined in current guidelines for risk detection. For triglyceride levels, women with elevated levels (Ն150 mg/ dL) were compared with those having levels Ͻ150 mg/dL. In unconditional logistic regression with adjustment for age and race, women with elevated levels of triglycerides had a 43% increased odds of ischemic stroke (OR, 1.43; 95% CI, 1.17-1.75). For LDL-C, women with high levels (Ն130 mg/dL) or moderate levels (100 -130 mg/dL) were compared with women with normal levels (Ͻ100 mg/dL). Compared with women with normal levels of LDL-C, those with high levels (OR, 1.18; 95% CI, 0.87-1.58) and moderate levels (OR, 1.04; 95% CI, 0.75-1.45) were at no significant increased odds of ischemic stroke. For HDL-C, women with low values (Ͻ50 mg/dL) were compared with those with values Ն50 mg/dL. In this analysis, women with low levels of HDL-C had an OR of ischemic stroke of approximately 1.24 (95% CI, 1.00 -1.54). 
Discussion
In this prospective evaluation of lipid and lipoprotein biomarkers associated with incident ischemic stroke, baseline level of triglycerides was a significant biomarker among postmenopausal women. Other biomarkers at baseline, including VLDL triglyceride, VLDL particle number, VLDL size, LDL particle number, IDL particle number, HDL cholesterol, HDL size, and the total cholesterol/HDL-C ratio were also associated with future ischemic stroke. Importantly, total cholesterol and LDL-C levels at baseline were not associated with ischemic stroke. For all markers, associations were markedly attenuated and-with the exception of triglycerides, VLDL size, and IDL particle number-no longer significant after adjustment for cardiovascular risk factors. To the best of our knowledge, this is the first study to directly address the magnitude of established and novel lipid biomarkers associated with the development of ischemic stroke.
Lipid Biomarkers and Ischemic Stroke
In previous epidemiological studies that have evaluated lipid biomarkers for the prediction of stroke, the data are conflicting. In the original Framingham Study for the prediction of stroke, total serum cholesterol was not predictive and therefore was removed from the final model. 29 Several large meta-analyses have noted a significant association between total cholesterol and stroke in young women, a finding not replicated in older women. 15, 18 A combined analysis of cohort studies noted a significant association between total cholesterol and stroke mortality in women younger than 55 years. 18 Data from the Atherosclerosis Risk in Communities (ARIC) Study 24 revealed weak and inconsistent associations between the risk of ischemic stroke and LDL-C, HDL-C, and triglycerides. In subgroup analysis according to sex, and consistent with the present study, women with triglyceride levels above the 87th percentile had a significant 2-fold greater adjusted risk for ischemic stroke than women in the lower quartile. 24 Recent data from the Women's Health Study found significant associations between the risk of ischemic stroke and established lipid biomarkers, including total cholesterol, LDL-C, and total cholesterol to HDL-C ratio. 20 The conflicting data for lipid biomarkers and stroke may be partly explained by the heterogeneity of the stroke end point, overcontrolling for potential biological mediators, evaluating only a selected subset of lipid biomarkers, and differences in risk factor/stroke relationships between older and younger populations and between women and men.
The current study demonstrated significant associations between several novel and established lipid and lipoprotein biomarkers and risk of ischemic stroke. Our data are noteworthy for several reasons. First, our data suggest that lipid and lipoprotein abnormalities may play a larger role in the risk of ischemic stroke than traditional lipid testing indicates. Lipoprotein abnormalities are common findings in patients with cardiometabolic risk (eg, smokers, overweight, physically inactive, hypertensive, metabolic syndrome). 27 Consistently, the association between lipid and lipoprotein biomarkers and risk of stroke was markedly attenuated after adjustment for these clinical variables. Second, the traditional measure of LDL-related cardiovascular disease risk, LDL-C, was not associated with incident ischemic stroke. LDL particle number, in contrast, was associated with future ischemic stroke in unadjusted analyses and in adjusted analyses in nondiabetic individuals. The seeming incongruity of our LDL-C findings with randomized clinical trial data showing a benefit of statin treatment on stroke incidence (RR, 0.83; PϽ0.001) 30 may partly be explained by the known LDL particle-lowering effect of statins. In addition, statin therapy reduces both triglycerides and IDL concentrations, probably contributing further to the stroke reduction observed in statin trials. 31 Other pharmacological effects of statin therapy such as improvement in endothelial function, promotion of atherosclerotic plaque stability, and modification of both inflammatory responses and thrombus formation may also be involved. 30, 32, 33 Third, although we did not find a significant interaction between lipid or lipoprotein biomarkers and hormone therapy use, the association between several lipid and lipoprotein biomarkers and stroke were greater in the group not using hormone therapy. These data are consistent with the Women's Health Study which found a significant interaction between total cholesterol and hormone use. 20 In that study, the increased risk of stroke with increasing levels of total cholesterol was only seen in women who did not use hormone therapy. 20 Finally, our study demonstrated that lipid and lipoprotein biomarkers may be important in the evolution of medical practice. Our findings raise the hypothesis that in addition to aiding in the prediction of ischemic stroke, changes in the levels of some of these factors through therapeutics or by lifestyle interventions may be beneficial in reducing the risk of stroke. In fact, subanalysis of 3 randomized, double-blind trials suggest that among patients with increased triglyceride levels, a 20 -40% reduction in triglyceride levels associates with a 30 -40% risk reduction in ischemic heart disease. 34 -36 Triglyceride Levels and Stroke Increasing evidence suggests that triglyceride level is important in assessing risk of atherosclerotic events. [37] [38] [39] [40] [41] [42] Furthermore, data suggest that women have a greater risk of cardiovascular events associated with hypertriglyceridemia than men. 40, 43 A meta-analysis of 17 epidemiological studies of more than 55 000 women and men demonstrated that triglyceride levels are associated with a 76% and 32% increased the risk of cardiovascular disease in women and men, respectively. 43 More recently, a prospective Danish study found that triglyceride levels were more predictive of ischemic heart disease in women than men. 40 Another Danish cohort study demonstrated a significant association between triglycerides and ischemic stroke, and this relationship was most pronounced among women. 44 In the present study of postmenopausal women, we found that triglyceride level was an important predictor of ischemic stroke in postmenopausal women. Triglyceride level remained an independent predictor in those with low and elevated values of LDL-C, total cholesterol, HDL-C, and total cholesterol to HDL-C ratio.
Although the mechanisms by which triglycerides affect ischemic stroke are unclear, several possibilities have been suggested. 41 Triglyceride-rich lipoproteins and elevated tri-glyceride levels appear to have a direct atherogenic effect, and high levels appear to be a marker of atherosclerotic and prothrombotic changes. 45 Elevated triglyceride levels are associated with abnormalities in the clotting-fibrinolytic cascade, which has been linked to ischemic stroke. 46 The effects of triglycerides probably are multifactorial and other potential mechanisms remain to be elucidated.
Limitations
Several limitations exist when interpreting this study. The ascertainment of lipid and lipoprotein biomarkers was at a single time point at study entry. However, in a reproducibility study for plasma biomarkers, the correlation coefficient was excellent for plasma lipids and lipoproteins collected several years apart. 47 Although women receiving lipid-lowering medicine at baseline were excluded from this analysis, use of cholesterol-lowering medicines may have changed over time. Nevertheless, these changes probably would be nondifferential and would tend to bias the results to the null. Another limitation is that multiple analyses were performed in this study, and no adjustments for multiple comparisons were made. Finally, the present study was conducted among mostly white postmenopausal women, and thus the predictive value of lipid biomarkers in premenopausal women and men as well as other race/ethnicity groups remains unknown.
Conclusions
The current study was designed to assess the relationship between lipid and lipoprotein biomarkers and development of ischemic stroke. With that in mind, we demonstrated that several lipid and lipoprotein biomarkers at baseline were associated with ischemic stroke. Though most associations for lipid and lipoprotein biomarkers were attenuated after multivariable adjustment, high levels of IDL particle number and VLDL size may be associated with an increased risk and require confirmation in future studies. From a clinical standpoint, level of triglycerides was independently associated with incident ischemic stroke. The present study supports the new guidelines from the American Heart Association and American Stroke Association on stroke prevention, which recognizes triglycerides as a risk factor for stroke. 42 Future studies should confirm our results and address the hypothesis whether lifestyle modification and/or pharmacological therapy aimed at reducing triglycerides are warranted for reducing the risk of ischemic stroke. NOTE: Due to stratification unconditional logistic regression was used; Each row is a separate model with stroke as the outcome and quartiles of that specific biomarker (quartile 1 left out of model as it is the reference) age and race as predictors
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